Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

1.

The cost and cost-effectiveness of gender-responsive interventions for HIV: a systematic review.

Remme M, Siapka M, Vassall A, Heise L, Jacobi J, Ahumada C, Gay J, Watts C.

J Int AIDS Soc. 2014 Nov 4;17:19228. doi: 10.7448/IAS.17.1.19228. eCollection 2014.

PMID:
25373519
[PubMed - in process]
Free PMC Article
2.

Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries.

Siapka M, Remme M, Obure CD, Maier CB, Dehne KL, Vassall A.

Bull World Health Organ. 2014 Jul 1;92(7):499-511AD. doi: 10.2471/BLT.13.127639. Epub 2014 Apr 1.

PMID:
25110375
[PubMed - in process]
Free PMC Article
3.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

PMID:
25104632
[PubMed - in process]
Free Article
4.

Financing tuberculosis control: promising trends and remaining challenges.

Vassall A, Remme M.

Lancet Glob Health. 2013 Aug;1(2):e62-3. doi: 10.1016/S2214-109X(13)70044-5. Epub 2013 Jul 24. No abstract available.

PMID:
25104150
[PubMed - in process]
Free Article
5.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2013 Dec 10;2(1):23-34.

PMID:
25083415
[PubMed]
Free PMC Article
6.

Financing structural interventions: going beyond HIV-only value for money assessments.

Remme M, Vassall A, Lutz B, Luna J, Watts C.

AIDS. 2014 Jan 28;28(3):425-34. doi: 10.1097/QAD.0000000000000076.

PMID:
24670525
[PubMed - indexed for MEDLINE]
7.

Financing essential HIV services: a new economic agenda.

Vassall A, Remme M, Watts C, Hallett T, Siapka M, Vickerman P, Terris-Prestholt F, Haacker M, Heise L, Haines A, Atun R, Piot P.

PLoS Med. 2013 Dec;10(12):e1001567. doi: 10.1371/journal.pmed.1001567. Epub 2013 Dec 17. No abstract available.

PMID:
24358028
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Paying girls to stay in school: a good return on HIV investment?

Remme M, Vassall A, Lutz B, Watts C.

Lancet. 2012 Jun 9;379(9832):2150. doi: 10.1016/S0140-6736(12)60944-1. No abstract available.

PMID:
22682463
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk